---
title: "Improving Gene Therapy Viral Vector Manufacturing Economics: Modelling Bioprocess Costs"
description: Learn about innovative tools in gene therapy and how they can help bring the cost of viral vector manufacturing down from Polyplus-transfection and Pall Corporation.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![New-ATE-Logo2019 (1)](https://bpi.bioprocessintl.com/hs-fs/hubfs/New-ATE-Logo2019%20(1).png?width=700&name=New-ATE-Logo2019%20(1).png)

# Improving Gene Therapy Viral

# Vector Manufacturing Economics:

# Modelling Bioprocess Costs

|  |
| --- |

## Presenters:

****![](https://bpi.bioprocessintl.com/hs-fs/hubfs/Speaker2-HS-Cropped.png?width=149&name=Speaker2-HS-Cropped.png)****

**Emmanuelle Cameau**  
*Strategic Technology Partnership Leader, Cell and Gene Therapy,*

Pall Corporation

 

Emmanuelle has more than 14 years of experience in biotechnology process development and GMP production. Highly skilled in the field of cell culture applications, Emmanuelle joined Pall Biotech almost 10 years ago as a Bioprocess Specialist (BPS) during her first four years. She then transitioned to the Bioreactor Applications Team, where she was Principal Bioreactor Specialist until March 2021 when she joined the newly formed Gene Therapy Business Unit as Strategic Technology Partnership Leader. Prior to Pall, Emmanuelle worked as Biotech Process Sciences Upstream Process Development Engineer at Merck Serono for four years. She received her degree in biotechnology engineering from the former Ecole Supérieure d’Ingénieurs de Luminy (now Polytech Marseille). Emmanuelle is a keen horse rider and enjoys competing in horse jumping competitions.

 

**![](https://bpi.bioprocessintl.com/hs-fs/hubfs/Speaker1-HS-Cropped.png?width=151&name=Speaker1-HS-Cropped.png)**

**Maxime Dumont**

*Cell & Gene Therapy Product Manager,*

Polyplus-transfection

Maxime Dumont is the Cell and Gene Therapy Product Manager at Polyplus-transfection®. With two master’s degrees in biochemistry, project management and marketing of pharmaceutical products, Maxime has managed the CGT transfection reagent portfolio for over four years.

## About this event:

#### Date: June 23, 2022

#### Time: 11 am EDT | 8 am PDT | 5 pm CET

#### Duration: 30 minutes

Gene therapy viral vector manufacturers strive to reduce time to market and cost per dose to ensure treatment affordability and patient access. Approved and commercialized AAV-based gene therapies Luxturna® and Zolgensma®, for patients suffering from vision loss and spinal muscular atrophy, are the first of many gene therapies that are expected to reach the market in the coming years. One major bottleneck is the cost per dose of the treatments, with Luxturna® costing almost half a million dollars per eye and Zolgensma® reaching two million dollars.

In this Ask the expert webinar with Polyplus and Pall Corporation, topics covered are:

- What have we learned from marketed gene therapies?
- How can we rely on cost-modelling to reduce manufacturing cost of viral vectors?
- What innovative tools in the gene therapy space can bring the cost of viral vector manufacturing down?

-  

-  

©2015 BioProcess International All Rights reserved